Both Mersana Therapeutics Inc. (NASDAQ:MRSN) and Realm Therapeutics Plc (NASDAQ:RLM) are Biotechnology companies, competing one another. We will contrast their institutional ownership, analyst recommendations, profitability, risk, dividends, earnings and valuation.

Valuation & Earnings

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Mersana Therapeutics Inc.	10.59M	20.07	64.26M	-2.43	0.00
Realm Therapeutics Plc	N/A	68.29	13.63M	0.00	0.00

In table 1 we can see Mersana Therapeutics Inc. and Realm Therapeutics Plc’s top-line revenue, earnings per share (EPS) and valuation.

Profitability

Table 2 has Mersana Therapeutics Inc. and Realm Therapeutics Plc’s net margins, return on assets and return on equity.

	Net Margins	Return on Equity	Return on Assets
Mersana Therapeutics Inc.	-606.80%	-110.4%	-49.8%
Realm Therapeutics Plc	0.00%	0%	0%

Insider and Institutional Ownership

Mersana Therapeutics Inc. and Realm Therapeutics Plc has shares owned by institutional investors as follows: 78.4% and 0%. Insiders owned roughly 0.1% of Mersana Therapeutics Inc.’s shares.

Performance

Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

	Performance (W)	Performance (M)	Performance (Q)	Performance (HY)	Performance (Y)	Performance (YTD)
Mersana Therapeutics Inc.	-37.91%	-4.15%	-18.7%	-68.3%	-74.65%	7.6%
Realm Therapeutics Plc	27.31%	41.64%	27.79%	0%	0%	83.75%

For the past year Mersana Therapeutics Inc. has weaker performance than Realm Therapeutics Plc

Summary

Realm Therapeutics Plc beats on 7 of the 9 factors Mersana Therapeutics Inc.

Mersana Therapeutics, Inc. is a biotechnology company that discovers, engineers, and develops antibody drug conjugates to cure various cancers. The company develops immune conjugate therapies to create drugs that enhance patientsÂ’ lives. It offers XMT-1522, a drug therapy for tumor models that express relatively low amounts of the HER2 protein; and human anti-HER2 antibody used in XMT-1522. Mersana Therapeutics, Inc. has strategic alliances with Takeda Pharmaceutical Company Limited; Merck Serono; and Asana BioSciences. The company was formerly known as Nanopharma Corp. and changed its name to Mersana Therapeutics, Inc. in November 2005. Mersana Therapeutics, Inc. was founded in 2001 and is based in Cambridge, Massachusetts.

Realm Therapeutics Plc, a biopharmaceutical company, focuses on developing therapies for the treatment of immune-mediated diseases in adults and children. Its product pipeline includes PRO22, a topical gel, which is conducting initial Phase II clinical studies for the treatment of atopic dermatitis. The company was formerly known as PuriCore plc and changed its name to Realm Therapeutics Plc in December 2016. Realm Therapeutics Plc is based in London, the United Kingdom.